

CITATION REPORT

List of articles citing

PD-1 as a potential target in cancer therapy

DOI: 10.1002/cam4.106

Cancer Medicine, 2013, 2, 662-73.

Source: <https://exaly.com/paper-pdf/56709180/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
349	[Immuno-Oncology "Coming of Age" - the next generation of immune checkpoint inhibitors]. 2014 , 37 Suppl 4, 6-9		
348	EBV-driven LMP1 and IFN- γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. 2014 , 5, 12189-202		246
347	PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. 2014 , 105, 1229-35		54
346	Indomethacin to the rescue of TRAIL-resistant melanomas. 2014 , 134, 1198-1199		3
345	Dendritic cell defects in the colorectal cancer. 2014 , 10, 3224-35		53
344	Cell exhaustion in HIV-1 infection: role of suppressor cells. 2014 , 9, 452-8		13
343	Dendritic cell cancer vaccines: from the bench to the bedside. 2014 , 5, e0024		9
342	Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy. 2014 , 5, 74		34
341	Maintenance therapy in ovarian cancer. 2014 , 26, 521-8		20
340	Nivolumab: a review of its use in patients with malignant melanoma. 2014 , 74, 1233-9		59
339	Immunologic and clinical effects of targeting PD-1 in lung cancer. 2014 , 96, 214-23		62
338	MABp1, a first-in-class true human antibody targeting interleukin-1 β in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. 2014 , 15, 656-66		141
337	Nivolumab: Immunotherapy in Malignant Melanoma. 2015 , 19, 430-2		7
336	Case of respiratory discomfort due to myositis after administration of nivolumab. 2015 , 42, 1008-9		57
335	Nivolumab in the treatment of malignant melanoma: review of the literature. 2015 , 8, 2045-51		15
334	The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis. 2015 , 8, 2617-25		23
333	Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. 2015 , 6, 24750-79		92

332	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. 2015 , 6, 7-17	48
331	Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. 2015 , 6, 12234-47	78
330	PD-L1 blockade for cancer treatment: MEDI4736. 2015 , 42, 474-83	71
329	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. 2015 , 3, 3	63
328	MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. 2015 , 94, 31-44	52
327	PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. 2015 , 3, 926-35	111
326	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. 2015 , 3, 1158-64	205
325	Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. 2015 , 21, 4286-93	469
324	The Pekin duck programmed death-ligand 1: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis. 2015 , 42, 111-20	7
323	Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. 2015 , 12, 53-64	157
322	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. 2015 , 26, 812-817	202
321	Immunotherapy of melanoma: present options and future promises. 2015 , 34, 115-28	49
320	Both PD-1 ligands protect the kidney from ischemia reperfusion injury. 2015 , 194, 325-33	45
319	High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. 2015 , 117, 165-70	36
318	CD4+CD25+CD127(low) Regulatory T Cells Play Predominant Anti-Tumor Suppressive Role in Hepatitis B Virus-Associated Hepatocellular Carcinoma. 2015 , 6, 49	20
317	Epstein-barr virus in gastro-esophageal adenocarcinomas - single center experiences in the context of current literature. <i>Frontiers in Oncology</i> , 2015 , 5, 73	53 23
316	Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. 2015 , 113, 107-18	28
315	Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. 2015 , 85, 703.e1-6	88

314	Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. 2015 , 42, 767-77		97
313	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. 2015 , 75, 563-75		16
312	PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 126, 203-11	2.2	135
311	Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. 2015 , 3, 149-60		169
310	Management of chronic myeloid leukemia in blast crisis. 2015 , 94 Suppl 2, S159-65		52
309	PD-1 and PD-L1 blockade in gastrointestinal malignancies. 2015 , 41, 893-903		44
308	Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. 2021 , 1-14		18
307	Hepatic stellate cells: central modulators of hepatic carcinogenesis. 2015 , 15, 63		64
306	Programmed death-1 & its ligands: promising targets for cancer immunotherapy. 2015 , 7, 777-92		16
305	Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. 2015 , 51, 2580-6		69
304	Long-term use of indomethacin leads to poor prognoses through promoting the expression of PD-1 and PD-L2 via TRIF/NF- κ B pathway and JAK/STAT3 pathway to inhibit TNF- α and IFN- γ in hepatocellular carcinoma. 2015 , 337, 53-60		16
303	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. 2015 , 17, 1064-75		356
302	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. 2015 , 27, 39-46		222
301	Mechanism of Action of Diseases and Drugs Part I. 2016 , 569-594		
300	Contemporary Treatment of Metastatic Renal Cell Carcinoma. 2016 , 10, 295		29
299	Contemporary Management of Prostate Cancer. 2016 , 5,		7
298	-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. 2017 , 10, 101-112		43
297	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability . PD-L1. 2016 , 7, 771-788		61

296	Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer. 2016 , 4, 103		30
295	Features of Memory-Like and PD-1(+) Human NK Cell Subsets. 2016 , 7, 351		83
294	A Perspective of Immunotherapy for Prostate Cancer. 2016 , 8,		21
293	Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. 2016 , 8,		21
292	PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. 2016 , 12, e1005642		72
291	Myasthenia gravis exacerbation associated with pembrolizumab. 2016 , 54, 506-7		40
290	Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. <i>Scientific Reports</i> , 2016 , 6, 20090	4.9	111
289	Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. 2016 , 4, 61		63
288	Regulation of effector function of CNS autoreactive CD4 T cells through inhibitory receptors and IL-7Rβ. 2016 , 13, 302		4
287	Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case report. 2016 , 95, e4283		29
286	Current Issues in the Diagnosis and Treatment of Endometrial Carcinoma. 2016 , 76, 170-175		10
285	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. 2016 , 17, 956-965		1007
284	Biomarkers associated with checkpoint inhibitors. 2016 , 27, 1199-206		112
283	Tim-3 identifies exhausted follicular helper T cells in breast cancer patients. 2016 , 221, 986-93		32
282	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. 2016 , 67, 46-54		54
281	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. 2016 ,		1
280	Cancer-Associated Tertiary Lymphoid Structures, from Basic Knowledge Toward Therapeutic Target in Clinic. 2016 , 99-125		
279	Monoclonal Antibodies Approved for Cancer Therapy. 2016 , 57-140		4

278	Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. 2016 , 7, 12499	484
277	Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. <i>Scientific Reports</i> , 2016 , 6, 30093	49 155
276	Europäische Kommission erteilt Zulassung für Nivolumab und Ipilimumab zur Behandlung des fortgeschrittenen Melanoms. 2016 , 15, 62-63	
275	Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. 2016 , 55, 505-21	29
274	Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access. 2016 , 14, 17	27
273	Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. 2016 , 34, 2619-26	359
272	Combinatorial prospects of nano-targeted chemoimmunotherapy. 2016 , 83, 308-20	85
271	Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. 2016 , 43, 113-23	8
270	Herbal Medicine Offered as an Initiative Therapeutic Option for the Management of Hepatocellular Carcinoma. 2016 , 30, 863-77	19
269	Pembrolizumab: A Review in Advanced Melanoma. 2016 , 76, 375-86	32
268	The management of immune-related adverse events associated with immune checkpoint blockade. 2016 , 1, 89-97	11
267	Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. 2016 , 34, 833-42	420
266	Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. 2016 , 24, 166-74	133
265	Cancer immunotherapy in veterinary medicine: Current options and new developments. 2016 , 207, 20-28	36
264	Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. 2017 , 139, 335-346.e3	269
263	Rate of Asparagine Deamidation in a Monoclonal Antibody Correlating with Hydrogen Exchange Rate at Adjacent Downstream Residues. 2017 , 89, 2361-2368	25
262	Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics. 2017 , 284, 1952-1966	82
261	PD-1 expression by canine T cells and functional effects of PD-1 blockade. 2017 , 15, 1487-1502	33

260	Epitope mapping reveals the binding mechanism of a functional antibody cross-reactive to both human and murine programmed death 1. 2017 , 9, 628-637	7
259	Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. 2017 , 56, 221-228	76
258	Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. 2017 , 28, 1388-1398	54
257	Phase I Trial of Intratumoral Injection of Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8 T-cell Infiltration. 2017 , 23, 4556-4568	92
256	Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. 2017 , 108, 590-597	27
255	Developmental history and application of CRISPR in human disease. 2017 , 19, e2963	6
254	Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma Management. 2017 , 26, 515-529	12
253	Pembrolizumab use for the treatment of advanced melanoma. 2017 , 17, 765-780	8
252	Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. 2017 , 5, 3	37
251	Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. 2017 , 38, 710-718	30
250	Association of PDCD1 gene markers with susceptibility to thyroid cancer. 2017 , 40, 481-486	11
249	Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. 2017 , 86, 115-124	49
248	Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. 2017 , 93, 387-394	24
247	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. 2017 , 73, 138-146	61
246	Oncolytic virus-induced cell death and immunity: a match made in heaven?. 2017 , 102, 631-643	27
245	[Malignant melanoma : Current status]. 2017 , 57, 814-821	4
244	Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India. 2017 , 31, 56-61	12
243	PD-1 and PD-L1 expression in bone and soft tissue sarcomas. 2017 , 49, 506-513	42

242	Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. 2017 , 27, 1034-1045	147
241	Using Model-Based "Learn and Confirm" to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial. 2017 , 6, 21-28	61
240	Phenotypic and Functional Analysis of Antigen-Specific T Cell Exhaustion. 2017 , 1514, 83-92	1
239	PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'. 2017 , 70, 558-567	162
238	Management of Adrenal Masses in Children and Adults. 2017 ,	4
237	PDCD5 regulates cell proliferation, cell cycle progression and apoptosis. 2018 , 15, 1177-1183	6
236	Aktuelle Aspekte zur Diagnostik und Therapie des Endometriumkarzinoms. 2017 , 38, 111-117	
235	PD-1 blockade enhances elotuzumab efficacy in mouse tumor models. 2017 , 1, 753-765	32
234	Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. 2017 , 10, 2349-2363	31
233	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. 2017 , 6, 51-71	76
232	Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma. 2017 , 10, 763-771	34
231	Nivolumab for the Treatment of Classical Hodgkin Lymphoma. 2017 , 33, 237-244	78
230	Prognostic and Predictive Value of PD-L1 in Patients with Lung Cancer. 2017 ,	
229	Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis. 2017 , 10, 3625-3634	18
228	Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer. 2017 , 10, 1101-1110	8
227	Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. 2018 , 14, 1869-1874	22
226	Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. 2018 , 139, 251-259	12
225	New Therapies in Head and Neck Cancer. 2018 , 4, 385-396	34

224	Relapsed Myasthenia Gravis after Nivolumab Treatment. 2018 , 57, 1893-1897	25
223	MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells. 2018 , 15, 4797-4804	20
222	Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF- β 2018 , 10,	239
221	PD-1 and cancer: molecular mechanisms and polymorphisms. 2018 , 70, 73-86	62
220	Signaling Transduction and Metabolomics. 2018 , 68-78	6
219	Immune checkpoint inhibitors: new strategies to checkmate cancer. 2018 , 191, 133-148	48
218	Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. 2018 , 472, 125-133	41
217	Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. 2018 , 36, 61-67	190
216	Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma. 2018 , 10, 4433-4444	21
215	Delayed Presentation of Isolated Adrenocorticotropin Insufficiency after Nivolumab Therapy for Advanced Non-small-cell lung carcinoma (NSCLC). 2018 , 2018,	8
214	Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. 2018 , 19,	51
213	Functionally impaired follicular helper T cells induce regulatory B cells and CD14 human leukocyte antigen-DR cell differentiation in non-small cell lung cancer. 2018 , 109, 3751-3761	16
212	Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma. 2018 , 5, 6-13	6
211	Differential role of CXCR3 in inflammation and colorectal cancer. 2018 , 9, 17928-17936	16
210	Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents. 2018 , 15, 5162-5173	17
209	Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. 2018 , 12, 262	32
208	Combinations of Bevacizumab With Cancer Immunotherapy. 2018 , 24, 193-204	89
207	Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials. 2018 , 28, 371-379	11

206	New developments in immunotherapy for lymphoma. 2018 , 15, 189-209	17
205	Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. 2018 , 97, e11936	56
204	Pembrolizumab beim fortgeschrittenen Ösophaguskarzinom. 2018 , 24, 76-78	
203	Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma. 2018 , 27, 259-265	11
202	PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer. 2018 , 9, 2938-2945	78
201	Construction of an anti-programmed death-ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells. 2018 , 16, 157-166	7
200	PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma. 2018 , 9, 2224-2231	10
199	Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. 2018 , 9, 727	25
198	Dual TGF- β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8 T cell response in esophageal squamous cell carcinoma. 2018 , 143, 2561-2574	49
197	Hyperprogression as a distinct outcome after immunotherapy. 2018 , 70, 16-21	69
196	Review of checkpoint immunotherapy for the management of non-small cell lung cancer. 2018 , 7, 63-75	36
195	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. 2018 , 50, 928-936	340
194	Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction. 2018 , 434, 11-21	22
193	Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer. 2019 , 22, 147-154	11
192	A case of checkpoint inhibitor-induced celiac disease. 2019 , 7, 203	11
191	Dysregulations of follicular helper T cells through IL-21 pathway in age-related macular degeneration. 2019 , 114, 243-250	3
190	Immunogenicity of pembrolizumab in patients with advanced tumors. 2019 , 7, 212	13
189	Clinical update on head and neck cancer: molecular biology and ongoing challenges. 2019 , 10, 540	167

188	Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies. 2019 , 20,		30
187	Drug-Induced Injury, Vascular, Congenital, Motility, Polyps, and Miscellaneous Disorders. 2019 , 479-522		
186	Drug-Induced Injury, Polyps, Congenital, and Miscellaneous Disorders. 2019 , 289-306		
185	Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. 2019 , 10, 2247		206
184	Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies. 2019 , 11, 1756287219882600		9
183	Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities. 2019 , 12, 6023-6032		15
182	The effects and safety of PD-1/PD-L1 inhibitors on head and neck cancer: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2019 , 8, 5969-5978	4.8	17
181	Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer. 2019 , 58, 3557-3562		7
180	Combining immunotherapies to treat non-small cell lung cancer. 2019 , 13, 621-634		0
179	PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. 2019 , 17, 207		10
178	Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?. 2019 , 7, S7		17
177	PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation. 2019 , 11, 266-272		10
176	Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development. 2019 , 18, 457-474		9
175	Current and emerging systemic therapies for cutaneous metastatic melanoma. 2019 , 20, 1135-1152		20
174	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. 2019 , 19, 196		68
173	Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. 2019 , 14, e0212513		137
172	Label-free classification of cells based on supervised machine learning of subcellular structures. 2019 , 14, e0211347		21
171	PD-L1 expression levels on tumor cells affect their immunosuppressive activity. 2019 , 18, 5399-5407		28

170	PD-1 Inhibitors in the Advanced Esophageal Cancer. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1418	5.6	16
169	Cancer Immunotherapy. 2019 , 231-250		
168	High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. 2019 , 24, 911-920		19
167	PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. 2019 , 234, 1313-1325		127
166	Epithelial-Stromal Interactions in Pancreatic Cancer. 2019 , 81, 211-233		18
165	Post-GWAS in prostate cancer: from genetic association to biological contribution. 2019 , 19, 46-59		41
164	Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. 2019 , 25, 1913-1922		25
163	Remarkable Short-Term Regression of a Posterior Mediastinum Metastasis From Primary Intraosseous Carcinoma Treated With Nivolumab: A Case Report. 2019 , 77, 555.e1-555.e6		1
162	The renal adverse effects of cancer immunotherapy. 2020 , 33, 467-481		5
161	Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors. 2020 , 9, 29-39		12
160	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. 2020 , 121, 109625		50
159	Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy. 2020 , 104, 147-157		41
158	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. 2020 , 21, 121-133		93
157	Higher densities of tumour-infiltrating lymphocytes and CD4 T cells predict recurrence and progression of ductal carcinoma in situ of the breast. 2020 , 76, 852-864		12
156	CDKL3 Targets ATG5 to Promote Carcinogenesis of Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020 , 10, 1602	5.3	2
155	Advances in targeted therapy for esophageal cancer. 2020 , 5, 229		72
154	Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). 2020 , 29, 1355-1364		16
153	Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. 2020 , 47, 487-510		8

152	Anticancer Effect of and Its Active Compound by Improving T-Cell Activity Blockade of PD-1/PD-L1 Interaction in Humanized PD-1 Mouse Model. 2020 , 11, 598556		5
151	Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. 2020 , 8, 758		39
150	PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma. 2020 , 44, 1050-1060		12
149	Downregulation of CYLD promotes IFN- γ -mediated PD-L1 expression in thymic epithelial tumors. 2020 , 147, 221-228		5
148	Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcome. 2020 , 11, 7246-7252		0
147	Development of Mannose-Modified Carboxylated Curdlan-Coated Liposomes for Antigen Presenting Cell Targeted Antigen Delivery. 2020 , 12,		6
146	Targeting Prostate Cancer Using Intratumoral Cytotopically Modified Interleukin-15 Immunotherapy in a Syngeneic Murine Model. 2020 , 9, 115-130		11
145	Hairy cell leukemia expresses programmed death-1. 2020 , 10, 115		3
144	CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models. <i>Oncolmunology</i> , 2020 , 9, 1747688	7-2	5
143	Exploration and validation of the effects of robust co-expressed immune-related genes on immune infiltration patterns and prognosis in laryngeal cancer. 2020 , 85, 106622		13
142	Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy. 2020 , 29, e13268		4
141	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. 2020 , 8,		30
140	Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre. 2020 , 146, 145-153		5
139	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. 2020 , 8,		30
138	Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series. 2020 , 30, 101114		
137	Preface. 2020 , ix-ix		
136	The Value of Gastrointestinal Biopsy. 2020 , 1-12		
135	Gastrointestinal Involvement by Systemic Disease. 2020 , 13-29		

- 134 Radiation and the Gastrointestinal Tract. **2020**, 30-51
- 133 Transplantation, Immunodeficiency, and Immunosuppression. **2020**, 52-64
- 132 Gastrointestinal Ischemia and Vascular Disorders. **2020**, 84-101
- 131 Paediatric Conditions. **2020**, 102-115
- 130 Gastrointestinal Dysplasia. **2020**, 116-130
- 129 Histology of Gastroesophageal Reflux Disease and Barrett's Oesophagus. **2020**, 157-167
- 128 Infections of the Oesophagus and Rare Forms of Oesophagitis. **2020**, 168-178
- 127 Assessment of Gastric Biopsies. **2020**, 179-185
- 126 Types of Gastritis. **2020**, 186-205
- 125 Coeliac Disease. **2020**, 215-235
- 124 Inflammatory Bowel Disease and the Upper Gastrointestinal Tract. **2020**, 236-244
- 123 Normal Lower Gastrointestinal Mucosa. **2020**, 245-259
- 122 Infectious Disorders of the Lower Gastrointestinal Tract. **2020**, 260-286
- 121 Jejunitis and Ileitis. **2020**, 287-309
- 120 Microscopic Colitis. **2020**, 310-324 1
- 119 Mimics of Inflammatory Bowel Disease. **2020**, 357-387 0
- 118 Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma. **2020**, 38, 5665-5677 8
- 117 Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. **2020**, 104, 533-541 5

116	Severe terminal ileitis induced by single-agent nivolumab administered every four weeks. 2020 , 26, 1516-1519	1
115	Advanced papillary thyroid carcinoma responding to nivolumab. 2021 , 27, 453-456	4
114	Chemotherapy and Immunotherapy in Urologic Oncology. 2021 ,	
113	Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma. 2021 , 17, 241-254	3
112	Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. 2021 , 7, 78-85	25
111	COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. 2021 , 11, 731-753	28
110	Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape. 2021 , 160, 279-284	5
109	Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative. 2020 , 1-9	7
108	Programmed cell death 1 (PDCD1) gene haplotypes and susceptibility of patients to basal cell carcinoma. 2021 , 48, 2047-2052	4
107	Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance. 2021 , 9,	6
106	Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma. 2021 , 21, 693-703	1
105	The construction and analysis of a ferroptosis-related gene prognostic signature for pancreatic cancer. 2021 , 13, 10396-10414	13
104	Personalized and targeted therapies. 2021 ,	
103	Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis. 2021 , 5, 459-467	0
102	Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions. 2021 , 93, 107403	6
101	Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer. 2021 , 187, 387-395	4
100	PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective. 2021 , 228, 153497	1
99	An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2021 , 334, 376-388	11.7 8

98	T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study. 2021 , 125, 717-724		0
97	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2021 , 12, 714483	5.6	3
96	Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. 2021 , 9, 1189		4
95	Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment. 2021 , 14, 4217-4228		3
94	Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120. <i>Frontiers in Pharmacology</i> , 2021 , 12, 723038	5.6	0
93	Enhancement of Immune Checkpoint Inhibitor-Mediated Anti-Cancer Immunity by Intranasal Treatment of Fucoidan against Metastatic Lung Cancer. 2021 , 22,		6
92	The PD-1/PD-L1 Checkpoint in Normal Germinal Centers and Diffuse Large B-Cell Lymphomas. 2021 , 13,		2
91	Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas. 2021 ,		1
90	Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors. 2021 , 102, 965-973		0
89	Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. 2021 , 19, 264		4
88	Biomaterials and devices for immunotherapy. 2022 , 97-133		
87	Nivolumab. 2016 , 297-317		1
86	Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy. 2020 , 69, 2075-2088		11
85	HIF1 β -mediated TRAIL Expression Regulates Lacrimal Gland Inflammation in Dry Eye Disease. 2020 , 61, 3		4
84	B7-H1-expressing antigen-presenting cells mediate polarization of protumorigenic Th22 subsets. 2014 , 124, 4657-67		55
83	A Case Report of Atezolizumab Induced Tumor Lysis Syndrome. 2019 , 20, 785-789		6
82	PD-1 gene rs10204525 and rs7421861 polymorphisms are associated with increased risk and clinical features of esophageal cancer in a Chinese Han population. 2020 , 12, 3771-3790		4
81	CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. 2016 , 7, 71455-71465		34

80	T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. 2016 , 7, 76902-76919	98
79	Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group. 2016 , 7, 80426-80434	29
78	Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. 2017 , 8, 7614-7624	24
77	Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. 2017 , 8, 42214-42225	61
76	Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. 2017 , 8, 74170-74177	18
75	Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy. 2020 , 23, 1065-1077	4
74	Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. 2020 , 12,	8
73	Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. 2015 , 4, 756-62	6
72	Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. 2017 , 49, 246-254	114
71	Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with -Mutant Non-small Cell Lung Cancer. 2018 , 50, 95-102	16
70	Promising Immunotherapeutic Approaches in Clinical Trials. 2016 , 351-416	1
69	Dendritic Cells. 2016 , 143-166	
68	Therapies for Locally Advanced and Metastatic Adrenocortical Carcinoma. 2017 , 257-275	
67	Investigation of the Molecular Diagnostic Market in Animals. 2019 , 51, 26-33	
66	Non-Neoplastic Pathology of the Gastrointestinal Tract: A Practical Guide to Biopsy Diagnosis. 2020	
65	Non-Neoplastic Diseases of the Anal Canal. 2020 , 434-445	
64	Normal Oesophageal, Gastric and Duodenal Mucosa. 2020 , 131-156	
63	Well-Defined Mannosylated Polymer for Peptide Vaccine Delivery with Enhanced Antitumor Immunity. 2021 , e2101651	3

62	Immunology and Immunotherapy of Ovarian Cancer. 2020 , 487-540		
61	Dendritic Cells in the Tumor Microenvironment. 2020 , 1273, 29-38		5
60	Nivolumab augments antitumor activity of invariant natural killer T cells.		0
59	Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy. 2021 , 9, 765552		3
58	Approach to Reporting Inflammatory Bowel Disease Biopsies. 2020 , 401-409		0
57	Ileal Pouch Anal Anastomosis. 2020 , 410-416		
56	Diverticular Disease, Mucosal Prolapse, and Related Conditions. 2020 , 417-433		
55	Drug-Induced Gastrointestinal Disease. 2020 , 65-83		
54	Duodenitis. 2020 , 206-214		
53	Inflammatory Bowel Disease Diagnosis. 2020 , 325-356		1
52	Index. 2020 , 446-462		
51	Complications of Inflammatory Bowel Disease. 2020 , 388-400		
50	Novel Therapies for Renal Cell Carcinoma. 2021 , 271-275		
49	Launch of Breakthrough Therapies Will Reshape Renal Cell Carcinoma Market. <i>P and T</i> , 2016 , 41, 523-5	1.4	2
48	Follicular helper T cell exhaustion induced by PD-L1 expression in hepatocellular carcinoma results in impaired cytokine expression and B cell help, and is associated with advanced tumor stages. <i>American Journal of Translational Research (discontinued)</i> , 2016 , 8, 2926-36	3	18
47	Prokaryotic expression of the extracellular domain of porcine programmed death 1 (PD-1) and its ligand PD-L1 and identification of the binding with peripheral blood mononuclear cells. <i>Canadian Journal of Veterinary Research</i> , 2017 , 81, 147-154	0.5	2
46	Colitis Induced by Immune-checkpoint Inhibitors. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2021 , 74, 599-605		1
45	Nano-trapping CXCL13 reduces regulatory B cells in tumor microenvironment and inhibits tumor growth.. <i>Journal of Controlled Release</i> , 2022 , 343, 303-313	11.7	2

44	COVID-19 AND CANCER COMORBIDITY: THERAPEUTIC OPPORTUNITIES AND CHALLENGES (RUSSIAN TRANSLATION). <i>Juvenis Scientia</i> , 2021 , 7, 28-70	0.1	
43	Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.. <i>Experientia Supplementum (2012)</i> , 2022 , 113, 1-57	2.2	○
42	A radiologist's guide to novel anticancer therapies in the era of precision medicine.. <i>European Journal of Radiology Open</i> , 2022 , 9, 100406	2.6	○
41	Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma. <i>Onkologie (Czech Republic)</i> , 2022 , 16, 10-15	0.1	
40	Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML.. <i>Blood</i> , 2022 ,	2.2	1
39	The expression of PD-1 and its ligands increases in Leishmania infection and its blockade reduces the parasite burden.. <i>Cytokine</i> , 2022 , 153, 155839	4	○
38	Coagulation and inflammation in cancer: Limitations and prospects for treatment.. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022 , 188727	11.2	1
37	Identification of a Lipid Metabolism-Associated Gene Signature Predicting Survival in Breast Cancer.. <i>International Journal of General Medicine</i> , 2021 , 14, 9503-9513	2.3	○
36	Prior exposure to microcystin alters host gut resistome and is associated with dysregulated immune homeostasis in translatable mouse models.		
35	Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy.. <i>Frontiers in Oncology</i> , 2022 , 12, 834564 ⁵³	5.3	○
34	Table_1.docx. 2020 ,		
33	image_1.PDF. 2018 ,		
32	Application and Research Progress of Immunosuppressive Agent-Based Systemic System Therapy in Advanced Hepatocellular Carcinoma. <i>Advances in Clinical Medicine</i> , 2022 , 12, 3079-3086	0	
31	High-throughput membrane-anchored proteome screening reveals PIEZO1 as a promising antibody-drug target for human esophageal squamous cell carcinoma. <i>Cancer Medicine</i> ,	4.8	○
30	Application of Pharmacokinetic/Pharmacodynamic Modeling to Bridge Mouse Antitumor Efficacy and Monkey Toxicology Data for Determining the Therapeutic Index of an Interleukin-10 Fc Fusion Protein. <i>Frontiers in Pharmacology</i> , 13,	5.6	○
29	Review of the Clinical Pharmacokinetics, Efficacy and Safety of Pembrolizumab. <i>Current Drug Metabolism</i> , 2022 , 23,	3.5	○
28	Impaired in vitro Interferon- γ production in patients with visceral leishmaniasis is improved by inhibition of PD1/PDL-1 ligation. <i>PLoS Neglected Tropical Diseases</i> , 2022 , 16, e0010544	4.8	○
27	Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses. <i>Onc Immunology</i> , 2022 , 11,	7.2	

26	Prior exposure to microcystin alters host gut resistome and is associated with dysregulated immune homeostasis in translatable mouse models. <i>Scientific Reports</i> , 2022 , 12,	4.9	2
25	Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression. <i>Frontiers in Oncology</i> , 12,	5.3	1
24	Antitumor immunotherapy and COVID-19 in cancer patients. 2022 , 21, 10-18	0.4	
23	Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy. 2022 , 22,		2
22	Colon Cancer Pharmacogenetics: A Narrative Review. 2022 , 10, 95		0
21	IL-12/18/21 pre-activation enhances the anti-tumor efficacy of expanded $\gamma\delta$ cells and overcomes resistance to anti-PD-L1 treatment.		
20	PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?. 2022 , 12, 653-671		1
19	A pyroptosis-related gene signature predicting survival and tumor immune microenvironment in breast cancer and validation. 2022 , 22,		0
18	Rs10204525 Polymorphism of the Programmed Death (PD-1) Gene Is Associated with Increased Risk in a Saudi Arabian Population with Colorectal Cancer. 2022 , 58, 1439		1
17	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. 2022 , 310, 121138		0
16	Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy. 2022 , 14, 5520		0
15	Adjuvant therapy options in renal cell carcinoma \square targeting the metastatic cascade.		0
14	Management of Metastatic Triple-negative Breast Cancer: Focus on Targeted Therapies. 2022 , 18, 98		0
13	Antitumor Immunotherapy: Effect of COVID-19 in Cancer Patients. 2022 ,		0
12	Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo.		0
11	Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion. 2023 , 95,		0
10	Research Status and Progress of PD-1/PD-L1 Inhibitors in the Treatment of Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer. 2023 , 13, 978-985		0
9	Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report. 2023 , 11, 311		0

- 8 Establishment of Cell-Based Assay System for Evaluating Cytotoxic Activity Modulated by the Blockade of PD-1 and PD-L1 Interactions with a Therapeutic Antibody. 1-11 ○
- 7 Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8 + tumor-infiltrating lymphocytes and patient prognosis. **2023**, 482, 755-766 ○
- 6 Identification of a PD1/PD-L1 inhibitor by Structure-Based Pharmacophore Modelling, Virtual Screening, Molecular docking and Biological Evaluation. ○
- 5 LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1-TINCR-USP20-PD-L1 axis. **2023**, 14, 1
- 4 Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma. ○
- 3 PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion. ○
- 2 Therapeutic potential of TRPM8 channels in cancer treatment. 14, ○
- 1 Immunotherapy in Prostate Cancer: Recent Advances and Future Directions. 51-61 ○